Home
Stock Ideas
Long Ideas
Healthcare
Summary
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential.
VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data.
Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030.
Technical analysis signals a neutral trend, but recent drug launches and upgraded revenue guidance provide a potential growth catalyst.
The risk of cash burn was highlighted as well, with about 1.6 years of cash runway expected at current burn rates unless it improves soon.
BlackJack3D/E+ via Getty Images
A Biotech Stock with a Q1 Earnings Miss, But Also a New Drug Approval
While many stocks I covered recently beat Q1 earnings estimates, this time I'll be covering a stock that actually…